CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Researchers used CRISPR to change the number of chromosomes in Arabidopsis by fusing chromosome arms, reducing the genome ...

UC Davis researchers engineered wheat that encourages soil bacteria to convert atmospheric nitrogen into plant-usable ...

Thinking about whether CRISPR Therapeutics stock is truly a bargain or just the next biotech craze? Let’s break down its value case together. After a sharp rally earlier this year, the stock is still ...

M OST STORIES about gene-edited children begin with He Jiankui, a rogue Chinese scientist who, in 2018, announced that he had ...

Although existing CRISPR-Cas-based imaging methods can target endogenous genomic sequences, their applications are limited by ...

It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...

A breakthrough study has just supercharged Fusarium venenatum (the fungus used in mycoprotein products like Quorn), turning ...

By reactivating a long-lost gene, researchers were able to lower uric acid levels and stop damaging fat accumulation in human ...

In a new study published in Trends in Biotechnology, researchers used a gene-editing technology called CRISPR to increase a ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP stock here.

America's next wave of scientific talent may come from Lambert High School, where students used CRISPR to develop a promising ...